Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.
| Publication Type | Academic Article |
| Authors | Xue Y, Lito P |
| Journal | Clin Cancer Res |
| Volume | 23 |
| Issue | 6 |
| Pagination | 1365-1367 |
| Date Published | 12/06/2016 |
| ISSN | 1557-3265 |
| Keywords | Lung Neoplasms, MAP Kinase Signaling System, Protein Kinase Inhibitors |
| Abstract | The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. Clin Cancer Res; 23(6); 1365-7. ©2016 AACRSee related article by Brant et al., p. 1471. |
| DOI | 10.1158/1078-0432.CCR-16-2576 |
| PubMed ID | 27923842 |